This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

YOGA-CF (Yoga Outcomes Get Assessed in Cystic Fibrosis)

Sponsored by Royal Brompton & Harefield NHS Foundation Trust

About this trial

Last updated 9 months ago

Study ID

YOGA-CF

Status

Recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
16+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started a year ago

What is this trial about?

The goal of this clinical trial is to investigate the effects of yoga participation for adults with cystic fibrosis. The main question it aims to answer is: does participation in yoga affect health-related quality of life for adults with cystic fibrosis? Researchers will compare a group completing a 12-week yoga programme alongside usual cystic fibrosis care, to a group completing usual care alone to see if the addition of yoga effects health-related quality of life.

What are the participation requirements?

Yes

Inclusion Criteria

Diagnosis of CF (confirmed by standard criteria; (Farrell et al. 2017)) Sixteen years of age or over Home internet access Ability to complete questionnaires in English Stable CF disease as judged by the investigator, a senior CF clinician

No

Exclusion Criteria

Inability to consent for treatment or measurement Current participation in another interventional study Current haemoptysis (greater than streaking in the sputum) Known pregnancy at time of recruitment Forced expiratory volume in 1 second (FEV1) below 30% predicted at baseline Use of ambulatory oxygen therapy, long-term oxygen therapy (LTOT) or non-invasive ventilation Current regular participation in yoga practice Current neurological or musculoskeletal injury which would prevent completion of yoga Diagnosis of osteoporosis (bone density Z score <-2.5) or history of spontaneous spinal fractures Uncontrolled gastroesophageal reflux Acute pulmonary exacerbation within 28 days of screening

Locations

Location

Status

Recruiting